Multiplicom N.V. announces the release of the SOMATIC 2 MASTR Plus kit for the detection of actionable somatic mutations in the genes EGFR, ERBB2, PIK3CA, PIK3R1 and PTEN enabling affordable, personalised cancer treatment.

With this extension of the somatic MASTR product line that already covers KRAS, NRAS, BRAF, cKIT, and PDGFRA, molecular pathologists have now a comprehensive toolbox for Next Generation Sequencing (NGS) containing ten genes with proven clinical utility in a large variety of solid tumours.

The somatic MASTR products for solid tumours are designed for amplification of formalin fixed paraffin embedded (FFPE) tissue derived DNA. Only a limited amount of DNA is needed and all mutations are analysed in a single sequencing run thereby reducing turnaround time and cost. The quality of the DNA extracted from the FFPE tissue and the amount required per test can best be determined using Multiplicom’s add-on QC Plex test.

Prof. Jurgen Del Favero, CTO of Multiplicom explains: “We have optimized these MASTR gene-panels in line with our philosophy of providing simple but efficient and reliable technology for the identification of mutations impacting patients care and treatment. Molecular pathology labs using our gene-panels are able to make a significant contribution to the cost-effective use of personalized medicine in oncology.”

Multiplicom develops, manufactures and commercializes molecular diagnostic assays, provided as kits, which enable personalized medicine.